{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T07:06:18Z","timestamp":1788937578433,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"DOI":"10.1007\/s11427-026-3438-4","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:09:19Z","timestamp":1788934159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting KRAS reprograms a Treg-dominant immunosuppressive microenvironment and sensitizes KRAS-mutant gastric adenocarcinoma to CTLA-4 immunotherapy"],"prefix":"10.1007","author":[{"given":"Xiaohuan","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yigang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiyo","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longtao","family":"Huangfu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongning","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"3438_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang, Y.J., Kim, Y.W., Yang, H.K., Chung, H.C., Park, Y.K., Lee, K.H., Lee, K.W., Kim, Y.H., Noh, S.I., Cho, J.Y., et al. (2012). Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379, 315\u2013321.","journal-title":"Lancet"},{"key":"3438_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jhep.2014.04.027","volume":"61","author":"A Carambia","year":"2014","unstructured":"Carambia, A., Freund, B., Schwinge, D., Heine, M., Laschtowitz, A., Huber, S., Wraith, D.C., Korn, T., Schramm, C., Lohse, A.W., et al. (2014). TGF-\u03b2-dependent induction of CD4+CD25+Foxp3+ Tregs by liver sinusoidal endothelial cells. J Hepatol 61, 594\u2013599.","journal-title":"J Hepatol"},{"key":"3438_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng, W., Kang, K., Zhao, A., and Wu, Y. (2024). Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol 17, 54.","journal-title":"J Hematol Oncol"},{"key":"3438_CR4","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1080\/15548627.2020.1714209","volume":"16","author":"E Dai","year":"2020","unstructured":"Dai, E., Han, L., Liu, J., Xie, Y., Kroemer, G., Klionsky, D.J., Zeh, H.J., Kang, R., Wang, J., and Tang, D. (2020). Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy 16, 2069\u20132083.","journal-title":"Autophagy"},{"key":"3438_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","volume":"19","author":"FG Dall\u2019Olio","year":"2022","unstructured":"Dall\u2019Olio, F.G., Marabelle, A., Caramella, C., Garcia, C., Aldea, M., Chaput, N., Robert, C., and Besse, B. (2022). Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol 19, 75\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"3438_CR6","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/gutjnl-2024-332125","volume":"74","author":"E De Martin","year":"2025","unstructured":"De Martin, E., Fulgenzi, C.A.M., Celsa, C., Laurent-Bellue, A., Torkpour, A., Lombardi, P., D\u2019Alessio, A., and Pinato, D.J. (2025). Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events. Gut 74, 1165\u20131177.","journal-title":"Gut"},{"key":"3438_CR7","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.ccell.2023.06.001","volume":"41","author":"J Griger","year":"2023","unstructured":"Griger, J., Widholz, S.A., Jesinghaus, M., de Andrade Kratzig, N., Lange, S., Engleitner, T., Montero, J.J., Zhigalova, E., Ollinger, R., Suresh, V., et al. (2023). An integrated cellular and molecular model of gastric neuroendocrine cancer evolution highlights therapeutic targets. Cancer Cell 41, 1327\u20131344.e10.","journal-title":"Cancer Cell"},{"key":"3438_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00262-024-03794-3","volume":"73","author":"C Guo","year":"2024","unstructured":"Guo, C., Dai, X., Du, Y., Xiong, X., and Gui, X. (2024a). Preclinical development of a novel CCR8\/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs. Cancer Immunol Immunother 73, 210.","journal-title":"Cancer Immunol Immunother"},{"key":"3438_CR9","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1007\/s11427-023-2444-5","volume":"67","author":"Z Guo","year":"2024","unstructured":"Guo, Z., Huang, J., Huo, X., Huang, C., Yu, X., Sun, Y., Li, Y., He, T., Guo, H., Yang, J., et al. (2024b). Targeting LTA4H facilitates the reshaping of the immune microenvironment mediated by CCL5 and sensitizes ovarian cancer to Cisplatin. Sci China Life Sci 67, 1226\u20131241.","journal-title":"Sci China Life Sci"},{"key":"3438_CR10","doi-asserted-by":"publisher","first-page":"2104426","DOI":"10.1080\/2162402X.2022.2104426","volume":"11","author":"RJ Harris","year":"2022","unstructured":"Harris, R.J., Willsmore, Z., Laddach, R., Crescioli, S., Chauhan, J., Cheung, A., Black, A., Geh, J.L.C., MacKenzie Ross, A.D., Healy, C., et al. (2022). Enriched circulating and tumor-resident TGF-\u03b2+ regulatory B cells in patients with melanoma promote FOXP3+ Tregs. Oncoimmunology 11, 2104426.","journal-title":"Oncoimmunology"},{"key":"3438_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y.Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., et al. (2021). First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27\u201340.","journal-title":"Lancet"},{"key":"3438_CR12","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang, Y.K., Boku, N., Satoh, T., Ryu, M.H., Chao, Y., Kato, K., Chung, H.C., Chen, J.S., Muro, K., Kang, W.K., et al. (2017). Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461\u20132471.","journal-title":"Lancet"},{"key":"3438_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","volume":"13","author":"SB Kemp","year":"2023","unstructured":"Kemp, S.B., Cheng, N., Markosyan, N., Sor, R., Kim, I.K., Hallin, J., Shoush, J., Quinones, L., Brown, N.V., Bassett, J.B., et al. (2023). Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov 13, 298\u2013311.","journal-title":"Cancer Discov"},{"key":"3438_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","volume":"35","author":"W Liao","year":"2019","unstructured":"Liao, W., Overman, M.J., Boutin, A.T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019). KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell 35, 559\u2013572.e7.","journal-title":"Cancer Cell"},{"key":"3438_CR15","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/cac2.12327","volume":"42","author":"C Liu","year":"2022","unstructured":"Liu, C., Zheng, S., Wang, Z., Wang, S., Wang, X., Yang, L., Xu, H., Cao, Z., Feng, X., Xue, Q., et al. (2022). KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer. Cancer Commun 42, 828\u2013847.","journal-title":"Cancer Commun"},{"key":"3438_CR16","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","volume":"41","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan, K.K., McAndrews, K.M., LeBleu, V.S., Yang, S., Lyu, H., Li, B., Sockwell, A.M., Kirtley, M.L., Morse, S.J., Moreno Diaz, B.A., et al. (2023). KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Cancer Cell 41, 1606\u20131620.e8.","journal-title":"Cancer Cell"},{"key":"3438_CR17","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio, M., Ascierto, P.A., Manzyuk, L., Motola-Kuba, D., Penel, N., Cassier, P.A., Bariani, G.M., De Jesus Acosta, A., Doi, T., Longo, F., et al. (2022). Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 33, 929\u2013938.","journal-title":"Ann Oncol"},{"key":"3438_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A., Le, D.T., Ascierto, P.A., Di Giacomo, A.M., De Jesus-Acosta, A., Delord, J.P., Geva, R., Gottfried, M., Penel, N., Hansen, A.R., et al. (2020). Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38, 1\u201310.","journal-title":"J Clin Oncol"},{"key":"3438_CR19","doi-asserted-by":"publisher","first-page":"eadt5511","DOI":"10.1126\/scitranslmed.adt5511","volume":"17","author":"KM McAndrews","year":"2025","unstructured":"McAndrews, K.M., Paradiso, F., Stalnecker, C.A., Chellakkan, B.S., Thege, F.I., Peng, D.H., Moreno Diaz, B.A., Sugimoto, H., Patel, S.I., Mahadevan, K.K., et al. (2025). An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer. Sci Transl Med 17, eadt5511.","journal-title":"Sci Transl Med"},{"key":"3438_CR20","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2767-9764.CRC-24-0172","volume":"4","author":"RJ Norgard","year":"2024","unstructured":"Norgard, R.J., Budhani, P., O\u2019Brien, S.A., Xia, Y., Egan, J.N., Flynn, B., Tagore, J.R., Seco, J., Peet, G.W., Mikucka, A., et al. (2024). Reshaping the tumor microenvironment of KRASG12D pancreatic ductal adenocarcinoma with combined sOS1 and MEK inhibition for improved immunotherapy response. Cancer Res Commun 4, 1548\u20131560.","journal-title":"Cancer Res Commun"},{"key":"3438_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41388-023-02929-7","volume":"43","author":"MG Oser","year":"2024","unstructured":"Oser, M.G., MacPherson, D., Oliver, T.G., Sage, J., and Park, K.S. (2024). Genetically-engineered mouse models of small cell lung cancer: the next generation. Oncogene 43, 457\u2013469.","journal-title":"Oncogene"},{"key":"3438_CR22","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.annonc.2022.07.005","volume":"33","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti, B., Alessi, J.V., Elkrief, A., Wang, X., Cortellini, A., Li, Y.Y., Vaz, V.R., Gupta, H., Pecci, F., Barrichello, A., et al. (2022). Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann Oncol 33, 1029\u20131040.","journal-title":"Ann Oncol"},{"key":"3438_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan, B., Halliday, N., and Sansom, D.M. (2018). CTLA-4: a moving target in immunotherapy. Blood 131, 58\u201367.","journal-title":"Blood"},{"key":"3438_CR24","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1053\/j.gastro.2019.09.026","volume":"157","author":"T Seidlitz","year":"2019","unstructured":"Seidlitz, T., Chen, Y.T., Uhlemann, H., Scholch, S., Kochall, S., Merker, S.R., Klimova, A., Hennig, A., Schweitzer, C., Pape, K., et al. (2019). Mouse models of human gastric cancer subtypes with stomach-specific CreERT2-mediated pathway alterations. Gastroenterology 157, 1599\u20131614.e2.","journal-title":"Gastroenterology"},{"key":"3438_CR25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1136\/gutjnl-2011-300050","volume":"61","author":"S Shimada","year":"2012","unstructured":"Shimada, S., Mimata, A., Sekine, M., Mogushi, K., Akiyama, Y., Fukamachi, H., Jonkers, J., Tanaka, H., Eishi, Y., and Yuasa, Y. (2012). Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut 61, 344\u2013353.","journal-title":"Gut"},{"key":"3438_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","volume":"39","author":"S Srivastava","year":"2021","unstructured":"Srivastava, S., Furlan, S.N., Jaeger-Ruckstuhl, C.A., Sarvothama, M., Berger, C., Smythe, K.S., Garrison, S.M., Specht, J.M., Lee, S.M., Amezquita, R.A., et al. (2021). Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade. Cancer Cell 39, 193\u2013208.e10.","journal-title":"Cancer Cell"},{"key":"3438_CR27","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/annonc\/mdy550","volume":"30","author":"R Sundar","year":"2019","unstructured":"Sundar, R., Huang, K.K., Qamra, A., Kim, K.M., Kim, S.T., Kang, W.K., Tan, A.L.K., Lee, J., and Tan, P. (2019). Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Ann Oncol 30, 424\u2013430.","journal-title":"Ann Oncol"},{"key":"3438_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"The Cancer Genome Atlas Research Network","year":"2014","unstructured":"The Cancer Genome Atlas Research Network (2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202\u2013209.","journal-title":"Nature"},{"key":"3438_CR29","doi-asserted-by":"publisher","first-page":"102070","DOI":"10.1016\/j.ctrv.2020.102070","volume":"89","author":"D Uprety","year":"2020","unstructured":"Uprety, D., and Adjei, A.A. (2020). KRAS: from undruggable to a druggable cancer target. Cancer Treat Rev 89, 102070.","journal-title":"Cancer Treat Rev"},{"key":"3438_CR30","doi-asserted-by":"publisher","first-page":"e001749","DOI":"10.1136\/jitc-2020-001749","volume":"9","author":"H Van Damme","year":"2021","unstructured":"Van Damme, H., Dombrecht, B., Kiss, M., Roose, H., Allen, E., Van Overmeire, E., Kancheva, D., Martens, L., Murgaski, A., Bardet, P.M.R., et al. (2021). Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy. J Immunother Cancer 9, e001749.","journal-title":"J Immunother Cancer"},{"key":"3438_CR31","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2023.06.037","volume":"165","author":"Y Xu","year":"2023","unstructured":"Xu, Y., Fu, J., Henderson, M.K., Lee, F., Jurcak, N., Henn, A., Wahl, J., Shao, Y., Wang, J., Lyman, M., et al. (2023). CLDN18.2 BiTE engages effector and regulatory T cells for antitumor immune response in preclinical models of pancreatic cancer. Gastroenterology 165, 1219\u20131232.","journal-title":"Gastroenterology"},{"key":"3438_CR32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-024-01631-9","volume":"17","author":"X Yang","year":"2024","unstructured":"Yang, X., and Wu, H. (2024). RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms. J Hematol Oncol 17, 108.","journal-title":"J Hematol Oncol"},{"key":"3438_CR33","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s11427-023-2472-4","volume":"67","author":"X Zhou","year":"2024","unstructured":"Zhou, X., Li, Y., Zhang, X., Li, B., Jin, S., Wu, M., Zhou, X., Dong, Q., Du, J., Zhai, W., et al. (2024). Hemin blocks TIGIT\/PVR interaction and induces ferroptosis to elicit synergistic effects of cancer immunotherapy. Sci China Life Sci 67, 996\u20131009.","journal-title":"Sci China Life Sci"},{"key":"3438_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","volume":"20","author":"G Zhu","year":"2021","unstructured":"Zhu, G., Pei, L., Xia, H., Tang, Q., and Bi, F. (2021). Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer 20, 143.","journal-title":"Mol Cancer"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-026-3438-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-026-3438-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-026-3438-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:09:20Z","timestamp":1788934160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11427-026-3438-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":34,"alternative-id":["3438"],"URL":"https:\/\/doi.org\/10.1007\/s11427-026-3438-4","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest. All patients provided written informed consent, and the Ethical Committee of Peking University Cancer Hospital (PKUCH) approved this study (No. 2025KT179). All authors had access to the study data and reviewed and approved the final manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}